Application of LincRNA (large intergenic non-coding RNA) in preparation of medicine for controlling tumor treatment drug resistance of methotrexate

A technology for regulating methotrexate and tumor treatment, which is applied in the direction of anti-tumor drugs, gene therapy, drug combination, etc., and can solve problems such as methotrexate resistance that have not been well solved

Active Publication Date: 2014-03-12
GUANGZHOU INST OF ADVANCED TECH CHINESE ACAD OF SCI
View PDF2 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] The prior art has not yet solved the problem of methotrexate drug resistance in clinical application
Moreover, there is no report in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of LincRNA (large intergenic non-coding RNA) in preparation of medicine for controlling tumor treatment drug resistance of methotrexate
  • Application of LincRNA (large intergenic non-coding RNA) in preparation of medicine for controlling tumor treatment drug resistance of methotrexate
  • Application of LincRNA (large intergenic non-coding RNA) in preparation of medicine for controlling tumor treatment drug resistance of methotrexate

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Embodiment 1MTX handles the impact on HT-29 cell morphology

[0029] use 10 -5 Colon cancer cells HT-29 were treated with MTX for 3 days, and the HT-29 cells without MTX treatment were used as the control to observe the effect of MTX on the morphology of HT-29 cells. The result is as figure 1 As shown, the colon cancer cells treated with MTX were in the form of stretched sheets or spindles ( figure 1 B), while untreated HT-29 cells are normally round ( figure 1 A).

[0030] The expression of embodiment 2H19 enhances the tolerance of MTX in HT-29 cells

[0031] HT-29 cells were divided into 2×10 4 Density seeded in 12-well plate, then 10 -6 μM and 10 -5 After treatment with MTX at μM concentration for 3 days, the cells were collected, RNA was extracted, and cDNA was obtained after reverse transcription. Then real-time fluorescent quantitative PCR technology was used to detect the expression abundance of H19 in HT-29 cells treated with two different MTX concentrat...

Embodiment 4H19

[0034] Example 4H19 overexpression enhances the tolerance of MTX in colon cancer HT-29 cells

[0035] The H19 overexpression plasmid was used to overexpress H19 in HT-29 cells. HT-29 cells according to 2×10 4 After the density was seeded in a 12-well plate, the H19 plasmid was transfected into HT-29 cells, and then 10 -5The μM concentration of MTX was treated for 3 days, and the cell viability was detected by the method of cell proliferation (MTT method). The result is as Figure 5 As shown, H19 overexpression increased the tolerance of MTX in HT-29 cells.

[0036] In summary, the results of Examples 3 and 4 indicate that the expression of H19 regulates the tolerance of MTX in HT-29 cells.

Embodiment 5H19

[0037] The impact of embodiment 5H19 on miRNAs expression and ABCC2 / ABCG2 expression

[0038] Some miRNAs were predicted by bioinformatics to target both H19 and ABCC2 / ABCG2. The relationship between each miRNAs and specific target genes is shown in Table 1.

[0039] Table 1 Relationship between miRNAs and specific target genes

[0040]

[0041]

[0042] HT-29 cells were divided into 2×10 4 After the density was seeded in a 12-well plate, the H19 plasmid was transfected into HT-29 cells, and then 10 -5 After treatment with MTX at μM concentration for 3 days, the cells were collected, RNA was extracted, and cDNA was obtained after reverse transcription. Firstly, the expression of drug resistance genes ABCC2 and ABCG2 was detected. The result is as Figure 6 As shown, H19 overexpression promoted the high expression of these two drug resistance genes. Then adopt real-time fluorescent quantitative PCR technique to detect wherein miR-186, miR-212, miR-132, miR-19a, miR-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of LincRNA (large intergenic non-coding RNA) in preparation of a medicine for controlling tumor treatment drug resistance of methotrexate. A coding sequence of LincRNA is shown in SEQ ID No:1. A non-coding RNA H19 (with a sequence shown in SEQ ID No:1) serves as a miRNA sponge or miRNA competitor and can be combined with miRNAs and the miRNAs can be combined with 3'-UTR of ABCC2/ABCG2 genes, so that the genetic expression of ABCC2/ABCG2 is inhibited, the tolerance of methotrexate in tumor cells is further improved, the non-coding RNA H19 possibly serves as a diagnostic marker or a molecular target of the methotrexate in tumor treatment, and the tumor treatment effect is improved.

Description

technical field [0001] The present invention belongs to the field of biomedicine. More specifically, the present invention relates to the application of a lincRNA (large intergenic non-coding RNA, intergenic long-chain non-coding RNA), in particular to the application of lincRNA in the preparation and regulation of Methotrexate (Methotrexate, MTX) drug application in tumor treatment drug resistance. Background technique [0002] Methotrexate is an anti-folate antineoplastic drug, which mainly hinders the synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting the growth and reproduction of tumor cells. As the earliest cytotoxic drug used in tumor treatment, methotrexate is effective against a variety of tumors including breast cancer, osteosarcoma, head and neck cancer, leukemia, and colon cancer. After long-term use, tumor cells will develop resistance to methotrexate, which hinders its clinical application. [0003] In order to better treat tum...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61P35/00A61P35/02
Inventor 付卫明张锦芳梁伟铖
Owner GUANGZHOU INST OF ADVANCED TECH CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap